Combined NNMT inhibitor treatment with reduced-calorie diet achieved 6.3 g cumulative weight loss versus 2.9 g with diet alone, and fat mass reduction was ten-fold greater with treatment (~29.3%) compared to diet switch alone (2.9%), while restoring fatty liver profiles to lean-control levels (Sampson et al., 2021)
Main Street, Unit 203, in historic downtown Littleton
Additionally, there has been significant growth and development in technology including Meibography providing the ability to image Meibomian glands, and a plethora of FDA approved medications and treatment modalities including, BlephEx, LipiFlow, TearCare, iLux, autologous serum, amniotic membranes, Meibomian gland probing, and Exosome therapy
The clinical programme ended in 2007